Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up – What’s Next?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares gapped up prior to trading on Monday . The stock had previously closed at $44.63, but opened at $50.45. Supernus Pharmaceuticals shares last traded at $48.16, with a volume of 701,960 shares trading hands.

More Supernus Pharmaceuticals News

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Merger creates greater scale: Supernus and Indivior agreed to a tax-free merger of equals that is expected to create a CNS-focused company with approximately $2.2 billion in annual revenue, 11 commercial medicines and $125 million in annual cost synergies. The combined company will be named Supernus, Inc.; Supernus CEO Jack Khattar will lead the business. Supernus shareholders will receive 1.5401 Indivior shares for each SUPN share. Supernus, Indivior merge to strengthen neuroscience drug portfolio
• Positive Sentiment: Revenue growth and guidance increase: Second-quarter revenue rose 32% year over year to $219.1 million, led by Qelbree, GOCOVRI, ONAPGO and ZURZUVAE collaboration revenue. Supernus raised full-year revenue guidance to $860 million-$890 million and adjusted operating earnings guidance to $150 million-$180 million. Supernus Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Growth products performed well: Qelbree sales increased 15% to $89.2 million, ONAPGO sales reached $13.5 million and ZURZUVAE collaboration revenue totaled $35.4 million. The company remains on track to seek FDA approval for a second ONAPGO supplier, potentially improving supply flexibility by mid-2027.
• Neutral Sentiment: Merger remains subject to approval: The transaction is expected to close in the fourth quarter of 2026, pending stockholder and regulatory approvals. Indivior shareholders would own approximately 56.5% of the combined company, compared with 43.5% for Supernus shareholders.
• Negative Sentiment: Reported profitability weakened: Supernus posted a GAAP net loss of $58.4 million, or $1.01 per share, versus a profit of $22.5 million a year earlier. Results included a $54.9 million non-cash impairment charge tied to APOKYN, while Trokendi XR, Oxtellar XR and APOKYN sales declined.
• Negative Sentiment: Deal-related risks: Indivior will fund a $1 billion special dividend partly through $650 million of new debt. Investors also face integration, execution and fixed-exchange-ratio risks. Separately, Halper Sadeh LLC is investigating whether Supernus shareholders are receiving a fair price, which could increase deal uncertainty. Halper Sadeh SUPN investigation

Analyst Ratings Changes

Several research firms have issued reports on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Cantor Fitzgerald raised their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Up 9.1%

The stock has a market capitalization of $2.82 billion, a PE ratio of -95.43, a price-to-earnings-growth ratio of 0.95 and a beta of 0.56. The company’s 50-day moving average is $46.27 and its 200 day moving average is $49.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 13.07% and a negative net margin of 3.74%.The company had revenue of $201.90 million for the quarter, compared to analysts’ expectations of $205.31 million. During the same period in the prior year, the firm posted $0.40 EPS. The firm’s revenue for the quarter was up 32.4% on a year-over-year basis. Sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Tudor Investment Corp ET AL purchased a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at about $1,434,000. Phocas Financial Corp. acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at about $4,042,000. Westover Capital Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $1,587,000. Stephens Investment Management Group LLC raised its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after purchasing an additional 61,120 shares during the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $994,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.